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Abstract
Background:  Idiopathic membranous nephropathy (IMN) is one of the most common causes of primary
nephrotic syndrome in adults. However, it is a relatively rare entity in the pediatric population and there is a
paucity of data about the incidence, prognosis, and optimal treatment of IMN in children and adolescents. We
conducted this study to evaluate pediatric patients with IMN in order to clarify the presentation, response to
therapy, and clinical outcome.
Methods: A retrospective chart review was performed on patients identified with biopsy-proven IMN between
1988–2005. Patients with systemic lupus erythematosus or hepatitis-related lesions were excluded. The following
data were tabulated: age, gender, ethnicity, presenting clinical and laboratory findings, proteinuria in a first
morning urine specimen, estimated glomerular filtration rate (GFRe), histopathology, type and duration of
treatment, and clinical status at final evaluation.
Results: 13 cases of IMN were identified out of 460 renal biopsies performed for evaluation of primary kidney
disease during the study interval. Mean age was 9.6 ± 4.6, gender 6 M:7 F, ethnicity 8 W:2 B:3 H. At the initial visit
hematuria was present in 9 patients, edema in 5, nephrotic-range proteinuria in 5, and hypertension in 3. Mean
urinary protein:creatinine ratio 3.3 ± 2.5 and all patients had a normal GFRe. Classic glomerular findings of IMN
were seen in all renal specimens, with concomitant interstitial changes in 2 cases. Treatment included an
angiotensin converting enzyme inhibitor or angiotensin receptor blocker in 11 cases. Most patients were also
given immunosuppressive medications – prednisone in 10, a calcineurin inhibitor in 5, and mycophenolate mofetil
or azathioprine in 3 patients. At the last follow-up, 42 ± 35 months after the diagnostic biopsy, 7 children were
hypertensive and the urine protein:creatinine ratio was 2.3 ± 3.1. The mean GFRe was 127 ± 57 mL/min/m2. Three
patients had Chronic Kidney Disease Stage 3, all of whom were also hypertensive.
Conclusion:  IMN is a rare but serious glomerulopathy in pediatrics. We estimate that it accounts for
approximately 3% of renal biopsies. Long-term prognosis is guarded because approximately 50% of patients may
have evidence of progressive kidney disease.
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Background
Although idiopathic membranous nephropathy (IMN) is
one of the most common etiologies of nephrotic syn-
drome in adults, it is an uncommon entity in the pediatric
population [1]. When it is identified in childhood, mem-
branous nephropathy is often a result of co-morbid ill-
nesses, such as SLE, hepatitis B or C infection, or
administration of various medications [1]. After excluding
these secondary causes, IMN is extremely rare. There is a
paucity of data about the prognosis and optimal treat-
ment of IMN in children and adolescents. Therefore, we
conducted this single-site, retrospective review of IMN in
children and adolescents to clarify these unresolved
issues.
Methods
A retrospective chart review was performed on all patients
identified with biopsy-proven idiopathic membranous
nephropathy (IMN) at Schneider Children's Hospital
between 1988–2005. Patients were identified by scanning
a database maintained in the Division of Nephrology.
They were eligible for inclusion in this study if they had
histopathological findings consistent with IMN. Patients
with SLE, hepatitis, or any other secondary causes were
excluded based on history and negative laboratory stud-
ies. Pathology records were reviewed to determine the
number of renal biopsies done during the study period for
the evaluation of potential primary kidney disease.
The following data at initial presentation were recorded:
age, gender, ethnicity, clinical and laboratory findings,
estimated glomerular filtration rate (GFRe), and histopa-
thology based on renal biopsy. Ethnicity was classified in
accordance with NIH guidelines. Clinical findings noted
at presentation included height, weight, and blood pres-
sure, and presence or absence of edema. Laboratory find-
ings included BUN, serum creatinine, albumin, and
cholesterol concentrations, hematuria (defined as positive
if the reading was more than trace), and urine protein:cre-
atinine ratio in a first morning specimen. Nephrotic-range
proteinuria was defined as a ratio >2. GFRe (mL/min/1.73
m2) was calculated using the age-appropriate Schwartz
formula [2]. Chronic kidney disease (CKD) was classified
according to the NKF/DOQI guidelines [3]. Blood pres-
sures were evaluated using the 2004 National High Blood
Pressure Education Program Working Group guidelines,
based on gender, age, and height percentiles [4]. The sum-
maries of the histopathology findings were obtained from
the pathological report. The presence or absence of inter-
stitial disease, the predominant immunoglobulin depos-
ited in subepithelial space, and presence of glomerular
sclerosis were noted.
For each patient, the type of medication and the total
duration of therapy were recorded. At the final follow-up
visit, the same data set extracted at the time of the disease
presentation was recorded.
Information was gathered using a pre-approved form and
data were deidentified and recorded by study number in
accordance with HIPAA guidelines. This retrospective
chart review was approved by the Institutional Review
Board of the North Shore-Long Island Jewish Health Sys-
tem.
Data are presented as mean ± SD. The difference between
groups was evaluated using the Student t-test. Differences
in outcome between groups defined by the presence or
absence of specific clinical findings at presentation were
assessed using the Fisher exact test. Results were consid-
ered statistically significant if the P value was less than
0.05.
Results
Over the 17-year study period, 13 patients with biopsy-
proven IMN were identified (Table 1). The mean age at
presentation was 9.6 ± 4.6 years (range: 4–17 years), and
9 patients were ≤ 10 years old. Six patients were male.
Eight patients were White, 2 patients were Black, and 3
were of Hispanic ethnicity. When they were first evalu-
ated, 9 patients had microscopic hematuria, 5 had periph-
eral edema, 5 had nephrotic-range proteinuria, and 3
patients were hypertensive. Less common symptoms were
abdominal pain noted in 2 patients and nocturnal enu-
resis in 1 patient. At presentation, all patients had a nor-
mal serum creatinine concentration and the GFRe was 155
± 34 mL/min/1.73 m2. No patient had a reduced GFRe,
i.e., <90 mL/min/1.73 m2. Six patients had hypoalbu-
minemia and all 13 patients had hypercholesterolemia.
The urinary protein:creatinine ratio at the initial assess-
ment was 3.3 ± 2.5. (Table 1)
Table 1: IMN in pediatric patients: clinical and laboratory data 
(N = 13)
Initial Visit 
N (%)
Final Visit 
n (%)
Mean Age 9.6 ± 4.6 --
Gender 6 M:7 F --
Ethnicity 8 W:2 B:3 H --
Hematuria 9 (69%) 6 (46%)
Peripheral Edema 5 (38%) 0
Proteinuria (protein:creatinine 
ratio)
3.3 ± 2.5 2.3 ± 3.1
Nephrotic-range Proteinuria 5 (38%) 3 (23%)
Hypoalbuminemia 6 (46%) 5 (38%)
Hypertension 3 (23%) 7 (54%)
Hypercholesterolemia 10 (77%) 5 (38%)
GFRemL/min/m2 155 ± 34 127 ± 57
CKD Stage 3–5 03  ( 2 3 % )
Abbreviations: CKD, Chronic kidney disease; GFRe, Estimated 
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The mean interval between referral to pediatric nephrol-
ogy and performance of a kidney biopsy was 1.7 ± 1.5
months. Characteristic histopathological findings of IMN
were seen in glomeruli in all specimens. Three patients
were identified as having glomerulosclerosis, 2 of whom
also had tubulointerstitial disease. Precise staging was
done in only 4 patients with 3 patients classified a Stage II
and 1 as Stage III. Eleven patients had subepithelial depos-
its on biopsy, 8 had intramembranous changes, and 2 had
resorption of deposits. Diffuse or localized podocyte
fusion was noted in 11 patients. The predominant immu-
noglobulin in the subepithelial or intramembranous
deposits was IgG in all 12 patients for whom this informa-
tion was recorded. Of these, 2 had combined IgG and IgM
and 1 had IgG and IgA deposition.
Eleven out of the 13 patients received an angiotensin con-
verting enzyme inhibitor (ACEI) or angiotensin receptor
blocker (ARB) for 20 ± 21 months. Ten patients were also
given immunosuppressive therapy with prednisone as the
first-line therapy. The criteria for the use of prednisone
were persistence of proteinuria after implementation of
treatment with ACEI and/or ARB. The initial dosage of
prednisone was 60 mg/m2/day for 4–6 weeks followed by
40 mg/m2 every other day. The duration of prednisone
treatment was 16 ± 19 months and the medication was
discontinued without tapering. Six of the patients went on
to receive one or more second-line drugs: cyclosporine (n
= 3), tacrolimus (n = 2), and/or mycophenolate mofetil/
azathioprine (n = 3). There were no consistent criteria or
clinical guidelines for the administration of these agents
during the study period. The cumulative duration of sec-
ondary immunosuppressive therapy was cyclosporine 22
± 12 months, tacrolimus 11 ± 2 months, and mycopheno-
late mofetil/azathioprine 15 ± 16 months. Proteinuria
fluctuated over the course of treatment without clear-cut
relapses or remissions. Figure 1 summarizes the overall
changes in treatment during the follow-up period.
At last follow-up, 42 ± 35 months after the diagnostic
biopsy, none of the patients had peripheral edema, 6 had
hematuria, 5 had hypoalbuminemia, and 4 were hyper-
tensive. In the complete cohort the GFRe was 127 ± 57 ml/
min/1.73 m2 and the urine protein:creatinine ratio was
2.3 ± 3.1 (Table 1). Although these values were lower than
original levels, the changes were not significant (P > 0.15).
3 patients had an elevated serum creatinine concentration
with a GFRe of 37 ± 9 mL/min/1.73 m2(CKD Stage 3),
compared with the remaining patients who had a GFRe
157 ± 22 mL/min/1.73 m2.
None of the following clinical features at initial presenta-
tion – hematuria, nephrotic-range proteinuria, or hyper-
tension – had any predictive value in determining which
patients would develop hypertension or compromised
GFR during the follow-up period, reflecting the small
sample size. Nonetheless, it is worth noting that all 3
patients with hypertension at the onset of the disease had
CKD and remained hypertensive at the last follow-up
visit.
Discussion
In this single center retrospective review, we describe 13
cases of IMN identified over a 17 year time period. Based
on a total of 715 renal biopsies done during the study
period, we estimate that the likelihood of a patient who
undergoes this procedure for evaluation of glomerular
disease having IMN is approximately 2%. Although IMN
is a rare disease in the pediatric population, it can occur in
the first decade of life as illustrated by our finding that 9
out of the 13 cases were documented in children less than
10 years of age. Males and females are equally affected and
the disease occurred in all ethnic groups. The predomi-
nance of white patients (62%), compared to Blacks (15%)
and Hispanics (23%), reflects the demographics of our
institution. Nonetheless, the gender and ethnic distribu-
tion in our series is similar to other reports of the disease
in children and adolescents [5].
The patients with IMN presented with varied signs and
symptoms, most commonly hematuria (75%), proteinu-
ria (50%), and edema (38%), consistent with other pub-
lications [5]. Patients may have hypoalbuminemia but
Summary of treatment provided to the patients with IMN Figure 1
Summary of treatment provided to the patients with IMN.
Total Sample
N=13
ACEI/ARB
n=11
1st line IS therapy
Prednisone
n=10
Current Therapy
No therapy
n=3
Current Therapy
2nd line IS therapy
n=5
Prednisone, n=4
CNI, n=1
MMF/AZA, n=3
Current Therapy
ACEI/ARB alone
n=5
Abbreviations: ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor 
blocker; AZA, azathioprine; CNI, calcineurin inhibitor; IS, immunosuppressive drug; MMF, 
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most have hypercholesterolemia. The reason for the disso-
ciation between the changes in serum albumin and cho-
lesterol is unclear. All patients had normal renal function,
but nearly a quarter had hypertension at the time of diag-
nosis.
In our study, histopathological staging of IMN in the renal
biopsies was not standard procedure [6]. There are several
reports in the literature indicating that in adults this pro-
cedure is helpful in predicting prognosis and the response
to drug therapy [7,8]. In children, Ramirez, et al [9]
reported an increased likelihood of progression to renal
insufficiency with Stage III and IV on initial biopsy com-
pared to Stage I or II lesions. However, Latham P et al [10]
described no correlation between initial histological stag-
ing and clinical outcome. Obana et al [11] recently
reported segmental versus diffuse glomerular involvement
and proposed that these patterns may represent two dis-
ease entities or subcategories of IMN. However, staging
was not evaluated as a prognostic tool in this article.
There is a great deal of discussion about the nature and
duration of treatment for IMN in adult patients without a
clear consensus on the most appropriate therapeutic
choice [12]. Prednisone is the standard first-line immuno-
suppressive therapy for IMN in pediatric patients and ster-
oid-resistant disease is the usual indication to initiate
treatment with another immunosuppressive agent. It is
difficult to assess the efficacy of the second-line immuno-
suppressive drugs prescribed in our study because these
medications were only initiated after the patient was
refractory to prednisone. Thus, bias may be introduced
based on administration to those who were refractory to
steroids and who may have had more severe kidney dis-
ease. In addition, we are unable to compare efficacy
between mycophenolate mofetil, azathioprine,
cyclosporine, and tacrolimus because the small number of
patients in our study precludes such an analysis. Moreo-
ver, some patients received two or more second-line
agents. This reflects the infrequent occurrence of IMN in
pediatrics and the single center nature of this report. A col-
laborative randomized clinical trial will almost certainly
be required to evaluate efficacy of immunosuppressive
medications in children and adolescents with IMN.
ACEI and/or ARB therapy are renoprotective in adult
patients with glomerular disease. We are unable to com-
pare outcomes in patients receiving ACEI or ARB therapy
versus those who did not, because only two patients were
not treated with one of these antihypertensive agents. If
these drugs are used alone, they may be insufficient to
adequately control blood pressure or retard disease in
patients with IMN. Thus, other antihypertensive medica-
tions should be prescribed to control blood pressure in
addition to maximum tolerated antiproteinuric doses of
ACEI and/or ARB therapy, given the increased incidence
of hypertension that we observed during the follow-up
period.
At the time of the final assessment, the mean GFRe
decreased from initial presentation, with 3 patients (23%)
having CKD Stage 3, described as moderate decrease in
GFRe [3]. These three patients were also hypertensive and
were the same three patients who presented with hyper-
tension at the onset of their disease. Moreover, 4 other
patients developed hypertension with maintenance of
normal GFRe. Thus, there was an increased proportion of
patients with hypertension from 23% at initial presenta-
tion to 54% at last the follow-up visit. In spite of immu-
nosuppressive therapy, involving more than one class of
drug in some patients, IMN can be a progressive disease in
children and adolescents.
In the last three decades, there have been 7 other reports
of IMN in children that contained at least 10 patients.
(Table 2) Most estimate an occurrence rate of IMN
between 1.0–6.7% of all renal biopsies performed at their
institution [9-11,13-16], which is consistent with our
observations. They all confirm that the disease can occur
in children <10 years old. The gender distribution ranges
Table 2: Prior reports of IMN in pediatric patients: a comparative review
Author, Year N Follow-up Period 
(yr)
Mean Age at 
Presentation (yr)
Age Range M:F Nephrotic at 
Presentation (%)
↓ GFR at 
last F/U (%)
HTN at 
last F/U (%)
Estimated 
Occurrence 
Rate (%)
Habib et al., 1973 50 1–10 NA 8 mo-14 yr 38:12 62 10 NA 3.7
Trainin et al., 1976 14 5.5 9 2–15 yr 6:8 79 29 NA 6.7
Ramirez et al., 1982 22 4.7 12 11 mo-19.9 yr 11:11 77 37 NA 5.7
Latham et al., 1982 14 6.4 10.5 3.5–14 9:5 79 21 NA 1.3
Tsukahara et al., 1993 12 5.9 7.7 2.9–15.8 yr 8:4 25 0 0 3
Obana et al., 2006 38 7.5 (SMGN); 12.4 
(GMGN)
7.6 1.5–16 yr 25:13 24 0 5% 2.4
Lee et al., 2006 19 28.5 9.5 1.7–14.9 9:10 89.5 15 NA 1
Current study 13 3.5 9.6 4–17 yr 6:7 38 23 54% 2.8
Abbreviations: GMGN, global membranous glomerulonephritis; HTN, hypertension; NA, not available; SMGN, segmental membranous 
glomerulonephritisBMC Nephrology 2007, 8:11 http://www.biomedcentral.com/1471-2369/8/11
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from an even split as in our series [9,15,16] to a male pre-
dominance [10,11,13,14]. There is wide variability in the
percentage of patients presenting with nephrotic-range
proteinuria, as well as the degree of long-term renal mor-
bidity. Our outcome data are most similar to Latham et al
[10] and Trainin et al [15] who reported that 21–29% of
patients manifested renal insufficiency at the last follow-
up. Most studies in adult patients with IMN suggest that at
least a quarter progress to CKD [17]. The presence of
hypertension alone at last follow-up in 4 out of our 13
patients, an observation not routinely reported in the
pediatric studies, raises additional concerns about the
prognosis in those patients. It is worth noting that in
Latham's study [10], children with IMN who had hyper-
tension at the onset of their disease had a lower likelihood
of entering remission. The marked variability in outcome
in pediatric patients with IMN may depend on differences
in ethnicity, biopsy practice patterns, and genetic factors.
This argues in favor of exercising caution when discussing
prognosis with individual pediatric patients found to have
IMN.
Conclusion
In summary, (1) IMN is a rare disease in childhood
accounting for approximately 3% of all biopsies done in
pediatric patients; (2) The long-term prognosis of IMN
should be considered guarded because nearly 50% of
patients will have CKD and/or hypertension after a 4 year
follow-up period; and (3) Although prednisone is the cur-
rent mainstay of immunosuppressive therapy, systematic
evaluation of the efficacy of other immunosuppressive
drugs in children and adolescents with IMN is urgently
required building on the experience of randomized clini-
cal trials performed in adult patients (18,19,20,21,22).
The rarity of IMN in pediatrics limits its study and the
challenge of identifying optimal treatment will mandate a
collaborative approach.
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